Skip to main content

Gore to Highlight Real-World Aortic Data at 45th Annual VEITHsymposium<sup>&reg;</sup>

Company shares findings from the Global Registry for Endovascular Aortic Treatment (GREAT), the largest industry-sponsored registry of aortic stent grafts

FLAGSTAFF, Ariz. (NOVEMBER 8, 2018) — W. L. Gore & Associates, Inc. (Gore) will highlight data gleaned from its Global Registry for Endovascular Aortic Treatment (GREAT) Study at the 45th Annual Symposium on Vascular and Endovascular Issues, VEITHsymposium® in New York. The company is featuring the data in multiple presentations facilitated by lead investigators. GREAT is the largest industry-sponsored registry of aortic stent grafts with enrollment and follow-up data from over 100 sites across 13 countries.

“We launched this registry in 2010 to evaluate and better understand how our family of aortic devices perform in real-world applications, and as a reflection of our continued commitment to advancing patient care in the treatment of aortic disease,” said Eric Zacharias, Vascular Business Leader. “The GREAT study draws from a pool of 5,000 patients who received one or more of the GORE® EXCLUDER® AAA Endoprostheses, GORE® EXCLUDER® Iliac Branch Endoprostheses, or Conformable GORE® TAG® Thoracic Endoprostheses. We are excited to share some of the conclusions and better inform our product offerings.”

GREAT had broad inclusion criteria with minimal exclusion criteria to more accurately reflect real world clinical practice. Treatment results will be tracked for 10 years. This follow-up has and will continue to provide valuable insights into the long-term durability and behavior of Gore aortic endografts.

“Traditionally, the industry has captured and shared data on migration, endoleak rates, rupture, conversions, and a few other data points,” said Ross Milner, Professor of Surgery and Co-Director of the Center for Aortic Diseases at the University of Chicago Medical Center and National Co-Principal Investigator for GREAT in the US. In contrast, the GREAT investigators have been able to query the data to get insights into previously unanswered, rarely asked, or often unexplored areas of treatment. Our lunch symposium will explore a few of those topics.”

Panel discussions on GREAT and the resulting observations will take place in the Main Pavilion, Mercury Ballroom, starting 12 p.m. EST Friday, November 16. The discussion will include the comprehensive portfolio of aortic products.

Friday, Nov. 16:

  • GREAT aortic endografting questions: What does the data reveal?
    Pierre Galvagni Silveira, MD, Florianopolis, Brazil
    Andrew Holden, MD, Auckland, New Zealand
    Santi Trimarchi, MD, Milan, Italy
  • The GREAT update: A review of one of the largest clinical registries for abdominal and thoracic aortic devices
    Beth Tohill, PhD, Flagstaff, Arizona
  • Acute and chronic Type B aortic dissections: Exploring the nuances behind the data
    Dennis Gable, MD, Dallas, Texas
  • Noncylindrical neck morphology: Incidence, effects, and risk of reintervention
    William Shutze, MD, Dallas, Texas
  • Performance in the narrow distal aorta: Findings and implications
    Ross Milner, MD, Chicago, Illinois

In addition to GREAT Registry discussions, Gore Medical will be hosting daily educational events at VEITHsymposium 2018, see full agenda here.

For more information on Gore aortic portfolio of products, visit

About VEITHsymposium

Now in its 45th year, VEITHsymposium provides vascular surgeons, interventional radiologists, interventional cardiologists and other vascular specialists with a unique and exciting format to learn the most current information about what is new and important in the treatment of vascular disease. The 5- day event features rapid-fire presentations from world renowned vascular specialists with emphasis on the latest advances, changing concepts in diagnosis and management, pressing controversies and new techniques.


Gore engineers medical devices that treat a range of cardiovascular and other health conditions. With more than 50 million medical devices implanted over the course of more than 45 years, Gore builds on its legacy of improving patient outcomes through research, education and quality initiatives. Product performance, ease of use and quality of service provide sustainable cost savings for physicians, hospitals and insurers. Gore is joined in service with clinicians and through this collaboration we are improving lives.

About Gore

W. L. Gore & Associates is a global materials science company dedicated to transforming industries and improving lives. Since 1958, Gore has solved complex technical challenges in demanding environments — from outer space to the world’s highest peaks to the inner workings of the human body. With more than 10,500 Associates and a strong, team-oriented culture, Gore generates annual revenues of $3.7 billion.